1.4Cyano phenyl at R1
The phenyl ring provides a planar aromatic surface and carries methoxy at the 4-position. The nitrile at the 3-position places a hydrogen-bond acceptor outside the ring.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The phenyl ring provides a planar aromatic surface and carries methoxy at the 4-position. The nitrile at the 3-position places a hydrogen-bond acceptor outside the ring.
The —CH₂CH₂OCH₃ chain attaches through its first methylene and presents an ether oxygen as a hydrogen-bond acceptor. Rotation about the carbon–carbon single bond changes the orientation of the ether relative to the attachment point.
Three methylene groups complete a four-membered ring around the carbon that bears the amide carbonyl. The ring holds both carbon branches in a shared framework and adopts a puckered geometry.
Carbon 2 of the thiazole bonds directly to the amide nitrogen and presents a five-membered aromatic surface. The thiazole nitrogen supplies a hydrogen-bond acceptor adjacent to the attachment carbon.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An analytical reagent test uses a triazolopyrimidinone with measured WRN inhibition as a low-activity control for recombinant WRN. A fluorescently labeled DNA duplex with a single-stranded loading tail reports unwinding after ATP addition. Each enzyme lot is tested with the compound and with matched solvent, and the difference between the two signals provides a measure of assay separation.
An oxetan-3-yl group replaces the five- or six-membered saturated heterocyclyl group at R1. The bond to the triazolopyrimidinone runs through the oxetane carbon opposite the ring oxygen, and the remaining substituents match those of the reference compound. A matched-pair test measures aqueous solubility and WRN inhibition under identical conditions.
An N-phenylsulfonamide replaces the N-phenylcarboxamide in an R2 side chain. The sulfonyl sulfur bonds directly to the side-chain carbon bearing the two RB groups, and the sulfonamide nitrogen bonds to phenyl and hydrogen. The triazolopyrimidinone core and the other attachment points match those of the reference compound for paired solubility and WRN inhibition measurements.
A 384-well plate holds 20 microliters per well of recombinant WRN, ATP, a fluorescent duplex DNA substrate, and test compound or control. A ten-point threefold dilution series starts at 30 micromolar compound, with dimethyl sulfoxide held at 0.5 percent in all wells. A plate reader measures fluorescence every 30 seconds for 20 minutes, and initial slopes normalized to solvent and enzyme-free controls yield the concentration response.
A triazolopyrimidinone concentration series is applied to paired human colorectal cell cultures consisting of a mismatch repair-deficient parental line and a derivative with the missing repair gene restored. The two cultures are plated in parallel with matched solvent controls and a baseline cell count at dosing. Automated nuclear counts after 72 hours provide growth-rate measurements for comparing the two cell backgrounds.
Software encodes each triazolopyrimidinone analog with a molecular fingerprint and links it to measured WRN inhibition and aqueous solubility. Separate Gaussian process models estimate both properties and their uncertainty for untested structures assembled from a catalog of available fragments. A batch selector ranks candidates by expected improvement in inhibition subject to a solubility threshold and updates both models as measured results enter the dataset.
Ring A is 3,3-difluoropiperidine-1,4-diyl, with attachment points at N1 and C4. Two independently selected RA groups are both fluorine and occupy the same carbon at C3.
R1 is 7-oxabicyclo[2.2.1]heptan-2-yl with zero additional substituents. One oxygen forms the one-atom bridge in the saturated seven-atom framework, and carbon 2 provides the attachment point.
R1 is (E)-but-2-en-1-yl and attaches through its terminal methylene. The internal double bond places the attachment-side methylene and terminal methyl on opposite sides of the alkene.
One RA occurrence is —S(O)₂N(CH₃)₂, with both R groups set to methyl. The parent structure bonds directly to sulfur, and the two sulfonyl oxygens serve as hydrogen-bond acceptors.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
For example, in certain embodiments, the compound of (I) is of Formula (I-a), or a salt thereof, wherein at least one instance of R2 is each instance of R2 is optionally substituted C1-30 alkyl, wherein one or more methylene units of R2 are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN) , —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RA · US 2018/0028664 A1 · ¶ 748
In certain embodiments, the heterocyclyl is substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, wherein 1, 2, or 3 atoms in the heterocyclic ring system are independently oxygen, nitrogen, or sulfur, as valency permits.B · US 2019/0125874 A1 · ¶ 310
A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon-carbon double or triple bonds.A · US 2018/0028664 A1 · ¶ 783
each x is independently an integer between 0-30, inclusive; and each instance is G is independently selected from the group consisting of optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN), —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, —C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(RA · US 2018/0028664 A1 · ¶ 750
In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”).A · US 2018/0028664 A1 · ¶ 788
In certain embodiments, the heteroaryl is substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur.B · US 2019/0125874 A1 · ¶ 315
Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents.B · US 2019/0125874 A1 · ¶ 316
In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.A · US 2018/0028664 A1 · ¶ 784
In certain embodiments, aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted. “Optionally substituted” refers to a group which may be substituted or unsubstituted (e.g., “substituted” or “unsubstituted” aliphatic, “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” orB · US 2019/0125874 A1 · ¶ 322
In certain embodiments, R1a, R1b, R2, R3, R4a, and R4b are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxyl, carbamoyl, carbonyldioxyl, amido, thiohydroxyl, alkylthioether, amino, alkylamino, dialkylamino, trialkylamino, cyano, and ureido, each of which may be substituted, as permitted by valency, with at least one substituent selected from the group consisting of alkyl, alkenyl, alkynyl, amino, alkylamino, dialB · US 2019/0125874 A1 · ¶ 85
In some embodiments, an aryl group has 14 ring carbon atoms (“C14 aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.A · US 2018/0028664 A1 · ¶ 786
Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the hetB · US 2019/0125874 A1 · ¶ 315
An empty cell means only that no passage was reproduced there.
However, even these “stealth” formulations have their limitations, including an inability to be repeatedly and frequently dosed, for example, over a period of days without loss of activity.A · US 2018/0028664 A1 · ¶ 2
This disclosure provides, in part, novel lipid nanoparticles (LNP) and LNP formulations that are less susceptible to recognition and thus clearance, by the immune system.A · US 2018/0028664 A1 · ¶ 6
In particular, there remains a need for delivery vehicles that form stable compositions, suitable for the delivery of therapeutic agents, such as mRNA, via nebulization.B · US 2019/0125874 A1 · ¶ 3
Polymers of the invention can be used to prepare stable formulations (e.g., particles) for nebulization or aerosol delivery.B · US 2019/0125874 A1 · ¶ 4
patent.fyi, US 2026/0356840 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356840/, SHA-256 66396ad57e2225b5fdccd1bf664c5ec8f0e7151442f0d1ad7c6cdfae5886ba89